Supplement encyclopedia

Carnitine family

Carnitine is a compound synthesized by the body and obtained from food; different forms are also sold in supplements.

Double-check conclusions and examine the sources before choosing a supplement.

Main conclusion

What it may offer

  • In trained men, a single dose of L-carnitine L-tartrate did not increase repetitions in a 20-minute CrossFit task; this single-dose regimen gave no grounds to expect more repetitions.
  • Over nine weeks, L-carnitine did not produce an additional increase in muscle mass or bench-press performance in men doing resistance training. Leg-press and peak-power measures differed between groups, so the result depends on the specific exercise.
  • In a small L-carnitine L-tartrate trial, young men reported less muscle soreness at some time points after exercise. A review of healthy adults also found less soreness after one and two days, but combined different preparations and highly varied results; this estimate cannot be attributed to one form.
  • After five weeks of L-carnitine L-tartrate, physically active adults rated their recovery and soreness after exercise more favorably. This is an overall well-being rating: it does not separately show how much pain decreased or recovery accelerated.
  • In a review of active people, L-carnitine improved individual endurance tests, but the magnitude of the overall effect was not established. The review therefore cannot predict a precise improvement for a specific exercise task.
  • Eight days of L-carnitine did not show a clear reduction in fatigue after cycling in healthy adults; under these conditions no fatigue relief was obtained.
  • Two very short studies in healthy young people did not show convincing improvements in memory and attention from L-carnitine. There are too few data to promise improvement in these abilities or consider absence of an effect definitively proven.
  • In a review of adults with differing health status, including healthy participants and patients, different forms of carnitine were associated with a small average weight decrease of about 1.2 kg versus control. These preliminary data do not justify promising that weight loss to everyone.
  • In the same review, evidence for reduced body fat mass was less reliable. No convincing reduction in waist circumference or body fat percentage was found.
  • In centenarians who became tired even with light activity, levocarnitine over 24 weeks reduced ratings of physical and mental fatigue and its overall severity versus placebo. This is a preliminary result specifically for this particular age group.

[1] [2] [3] [4] [5] [6] [7] [8] [9] [10]

What was studied

  • Trained men performed a 20-minute CrossFit task after one dose or undertook resistance exercise for nine weeks. In a separate crossover experiment, healthy adults took L-carnitine for eight days, after which fatigue from cycling was assessed.
  • In healthy young men, soreness after resistance exercise was assessed 24–72 hours after three-week dosing periods; in physically active men and women, an overall recovery and soreness rating was assessed after five weeks. These are different tasks and follow-up periods.
  • The endurance review included active people, single doses and courses from two to 24 weeks. The memory and attention review included healthy young people; dosing was single or lasted three days, so these experiments did not assess long-term results.
  • Weight and body composition were studied in adults with differing health status, including healthy participants and patients. Different forms of carnitine were used, sometimes with diet, training or other interventions; the overall review result cannot be attributed to one supplement.
  • Fatigue was separately studied in centenarians who became tired with light activity: they took levocarnitine for 24 weeks. This is a different group from the healthy adults in the short study of fatigue after cycling.

[1] [2] [3] [4] [5] [6] [7] [8] [9]

Forms studied

  • L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine are different forms; L-carnitine L-tartrate is a salt. When choosing a supplement, distinguish its form and stated amount: results for one form cannot automatically be transferred to another.
  • The recovery trial used 3 g L-carnitine L-tartrate daily for five weeks; the authors stated that this amount contains 2 g L-carnitine. This conversion applies to that studied preparation and does not establish a universal dose.

[1] [2]

Food sources

  • Carnitine can be obtained from meat, poultry, fish and dairy products; meat generally contains more. Thus dietary sources include different food groups, not only supplements.
  • Plant foods such as whole-grain bread, asparagus and avocado contain comparatively little. Dietary carnitine should not be equated with acetyl-L-carnitine, propionyl-L-carnitine or the mass of a salt in a supplement.

[1] [2]

Effects and studied questions

How to read the certainty scale 1–4

Certainty is rated separately for each outcome. 1 is very low, 2 is low, 3 is moderate and 4 is high.

Goal or questionResultConfidenceStudiesPopulation studiedKey sources
CrossFit repetition countIn 20 trained men, a single 3 g dose of L-carnitine tartrate did not increase repetitions in a 20-minute task.202.4±69.9 versus 204.5±78.8 repetitions; p=0.810. A paired contrast was separately published as +2.85 (95% CI −15.6…+21.3), p=0.750; estimates do not fully agree.
2/4 LowLow confidence in the specific pairwise comparison: reported results conflict and the interval is wide with 20 participants; the absence of significant improvement does not prove equivalence.
11 trialAcute L-Carnitine Supplementation Does Not Improve CrossFit Performance: A Randomized, Double-Blind, Placebo-Controlled Crossover Study ↗20 trained men, crossover RCT
  1. Acute L-Carnitine Supplementation Does Not Improve CrossFit Performance: A Randomized, Double-Blind, Placebo-Controlled Crossover Study ↗
Individual endurance testsPositive results were observed in individual tests; the magnitude of the overall effect was not established.The available abstract does not provide a pooled numerical estimate. Across the review, 15 studies had some concerns about risk of bias and 3 had high risk.
Not assessedConfidence cannot be assessed for the current outcome: it is not established exactly which trials, tests and regimens make up the positive and negative comparisons or how precise those comparisons are. A reproducible effect for a specific test cannot be distinguished from selective, scattered findings.
11 systematic review; 18 studies in the entire review, not the number of studies of an individual testAcute and Chronic L-Carnitine Supplementation Enhances Endurance Performance Without Consistent Effects on Substrate Oxidation in Active Individuals: A Systematic Review ↗Active people; 18 studies refer to the whole review, and numbers of participants and studies for individual tests are not specified in the abstract.
  1. Acute and Chronic L-Carnitine Supplementation Enhances Endurance Performance Without Consistent Effects on Substrate Oxidation in Active Individuals: A Systematic Review ↗
muscle massThe nine-week study found no additional change in muscle mass between groups.no statistically significant between-group differences found
2/4 LowLow confidence: one small trial with unclear reporting of participants. An additional change in the body composition measure was not statistically established; this does not prove absence of an effect.
11 trialEffects of nine weeks L-Carnitine supplementation on exercise performance, anaerobic power, and exercise-induced oxidative stress in resistance-trained males ↗23 resistance-trained men
  1. Effects of nine weeks L-Carnitine supplementation on exercise performance, anaerobic power, and exercise-induced oxidative stress in resistance-trained males ↗

The study count refers to the cited source. Reviews with overlapping trials and outcomes from one study are not added together.

Daily intake requirements and upper limits

Intake and studied regimens
ContextDetails
Intake recommendationsHealthy adults generally synthesize sufficient carnitine; no recommended daily intake has been established. Inherited or secondary deficiency is considered separately from nutrition in healthy people.
Intake and studied regimensStudied doses and durations depend on outcome and form; no universally effective or safe dose has been established, and no tolerable upper intake level has been established. The quality of any specific product was not assessed.

Carnitine - Health Professional Fact Sheet ↗

Forms

L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine are different forms; L-carnitine L-tartrate is a salt. The salt dose cannot automatically be equated to the mass of L-carnitine; a mixture and intravenous administration cannot be extrapolated to a single oral form.

Guidance for each goal

CrossFit repetition count2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the specific pairwise comparison: reported results conflict and the interval is wide with 20 participants; the absence of significant improvement does not prove equivalence.

In 20 trained men, a single 3 g dose of L-carnitine tartrate did not increase repetitions in a 20-minute task.

Study findings. In 20 trained men, a single 3 g dose of L-carnitine tartrate did not increase repetitions in a 20-minute task.

Studied regimen3 g onceoral L-carnitine L-tartrate
Duration and populationsingle dose20 trained men, crossover RCT

Comparison with placebo; 7-day washout between periods

Individual endurance testsNot assessedRead moreCollapse
Confidence
Not assessedConfidence cannot be assessed for the current outcome: it is not established exactly which trials, tests and regimens make up the positive and negative comparisons or how precise those comparisons are. A reproducible effect for a specific test cannot be distinguished from selective, scattered findings.

Positive results were observed in individual tests; the magnitude of the overall effect was not established.

Study findings. Positive results were observed in individual tests; the magnitude of the overall effect was not established.

Studied regimen2–15 g once or 2–3 g/day in the reviewOral L-carnitine, protocols varied
Duration and populationAcute protocols and 2–24-week coursesActive people; 18 studies refer to the whole review, and numbers of participants and studies for individual tests are not specified in the abstract.

Comparison with placebo

muscle mass2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence: one small trial with unclear reporting of participants. An additional change in the body composition measure was not statistically established; this does not prove absence of an effect.

The nine-week study found no additional change in muscle mass between groups.

Study findings. The nine-week study found no additional change in muscle mass between groups.

Studied regimen2 g/dayoral L-carnitine
Duration and population9 weeks23 resistance-trained men

Comparison with placebo; both groups trained

volume and repetitions in the third bench-press set2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence: one small trial with unclear reporting of participants. An additional change in bench-press volume and repetitions was not statistically established; this does not prove absence of an effect.

The nine-week study found no additional between-group change in press volume or repetition count.

Study findings. The nine-week study found no additional between-group change in press volume or repetition count.

Studied regimen2 g/dayoral L-carnitine
Duration and population9 weeks23 resistance-trained men

Comparison with placebo; both groups trained

leg-press volume2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence: risk of bias in allocation and analysis, and limited precision of the small comparison. The time × group interaction for leg-press volume, p=0.01, concerns repeated measurements, not a separate pairwise difference at week nine.

The change in the leg-exercise measure differed between groups; time×group interaction p=0.01.

Study findings. The change in the leg-exercise measure differed between groups; time×group interaction p=0.01.

Studied regimen2 g/dayoral L-carnitine
Duration and population9 weeks23 resistance-trained men

Comparison with placebo; both groups trained

Wingate peak power2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence: risk of bias in allocation and analysis, and limited precision of the small comparison. The time × group interaction for peak power, p=0.03, is not a separate pairwise estimate at week nine; the power measures come from one sample.

The change in anaerobic power differed between groups; time×group interaction p=0.03.

Study findings. The change in anaerobic power differed between groups; time×group interaction p=0.03.

Studied regimen2 g/dayoral L-carnitine
Duration and population9 weeks23 resistance-trained men

Comparison with placebo; both groups trained

self-rated muscle pain after exercise2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence: eight participants, subjective pain and unestablished blinding. Soreness was lower at some doses and time points; the reliability of the magnitude and reproducibility are limited.

In a very small crossover trial, soreness on a separate scale after exercise was lower at some time points; precision and reproducibility are limited.

Study findings. In a very small crossover trial, soreness on a separate scale after exercise was lower at some time points; precision and reproducibility are limited.

Studied regimen1 or 2 g/day as described in the primary abstractoral L-carnitine L-tartrate
Duration and population3 weeks per dose; resistance exercise8 healthy young men, randomized repeated-measures study

Comparison with 0 g

Soreness rating 24 h after exerciseNot assessedRead moreCollapse
Confidence
Not assessedConfidence has not yet been assessed: for the pooled result at 24 hours, it is not established which doses and scales were included in the calculation or how repeated comparisons of the same participants were handled. The reported confidence interval does not resolve this.

In the pooled analysis, soreness at 24 hours after exercise was lower, but study results varied greatly.

Study findings. In the pooled analysis, soreness at 24 hours after exercise was lower, but study results varied greatly.

Studied regimen1–2 g/day in the descriptive corpus; exact correspondence of individual regimens to pooled-analysis rows is unknown.Carnitine or L-carnitine L-tartrate; studied preparations differed.
Duration and population3 weeks, in one study 3 weeks and 3 days; soreness assessed at 24 h after exercise.Active adults; 50 people are listed in the descriptive corpus of four articles; the sample size of this particular analysis is not established.

Comparison with control during exercise; some trials used a crossover design.

Soreness rating 48 h after exerciseNot assessedRead moreCollapse
Confidence
Not assessedConfidence has not yet been assessed: for the pooled result at 48 hours, it is not established which doses and scales were included in the calculation or how repeated comparisons of the same participants were handled. The reported confidence interval does not resolve this.

In the pooled analysis, soreness at 48 hours after exercise was lower, but study results varied greatly.

Study findings. In the pooled analysis, soreness at 48 hours after exercise was lower, but study results varied greatly.

Studied regimen1–2 g/day in the descriptive corpus; exact correspondence of individual regimens to pooled-analysis rows is unknown.Carnitine or L-carnitine L-tartrate; studied preparations differed.
Duration and population3 weeks, in one study 3 weeks and 3 days; soreness assessed at 48 h after exercise.Active adults; 50 people are listed in the descriptive corpus of four articles; the sample size of this particular analysis is not established.

Comparison with control during exercise; some trials used a crossover design.

combined perceived recovery and soreness scale PRS3/4 ModerateRead moreCollapse
Confidence
3/4 ModerateModerate confidence: in one trial, a normalized recovery and soreness score worsened less. The precise and practically meaningful magnitude of the difference remains uncertain; the measure is not equivalent to a separate pain assessment.

In a small trial, perceived recovery after exercise improved; the scale does not isolate an effect on pain alone.

Study findings. In a small trial, perceived recovery after exercise improved; the scale does not isolate an effect on pain alone.

Studied regimen3 g tartrate/day, equivalent to 2 g L-carnitineoral L-carnitine L-tartrate Carnipure
Duration and population5 weeks, exercise test80 physically active adults aged 21–65 randomized; 73 completed

Comparison with placebo

perceived fatigue after cycling3/4 ModerateRead moreCollapse
Confidence
3/4 ModerateModerate confidence in the exact comparison: the study did not establish a clear improvement in subjective fatigue, but with 18 participants the magnitude of the difference remains imprecise; this is not proof of no effect.

A short study showed no clear effect on fatigue after cycling.

Study findings. A short study showed no clear effect on fatigue after cycling.

Studied regimen1 g/day expressed as L-carnitine; this is 1.462 g L-carnitine L-tartrate in the studied preparationOral L-carnitine L-tartrate
Duration and population8 days18 healthy adults, crossover study

Comparison with placebo

body weight2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the average estimate for the mixed body of evidence because of risk of bias and heterogeneity. The average obtained does not predict an individual result or establish an effect for each form or regimen.

Average weight fell slightly in the studies; the result does not predict individual weight loss.

Study findings. Average weight fell slightly in the studies; the result does not predict individual weight loss.

Studied regimen250–4000 mg/day in the listed protocols; forms and dose basis differThe study set includes L-carnitine, acetyl-L-carnitine [82], L-carnitine L-tartrate [80,83] and glycine propionyl-L-carnitine [98]; some trials included co-interventions. Salt mass and free carnitine content in the corresponding rows are not equated; do not automatically treat these regimens as identical.
Duration and population3–48 weeksAdults with different health status, including healthy participants and patients; 1520 participants reported by the review for this outcome. The number of independent participants in the analysis is unconfirmed.

Comparison with control

fat mass2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the overall difference in fat mass: the effect was not confirmed in the analysis of higher-quality randomized controlled trials, and the result is sensitive to exclusion of one study. This does not prove absence of an effect.

In the overall analysis fat mass decreased, but the fat-mass effect was not confirmed in the analysis restricted to high-quality RCTs.

Study findings. In the overall analysis fat mass decreased, but the fat-mass effect was not confirmed in the analysis restricted to high-quality RCTs.

Studied regimen2000–4000 mg/day in the listed protocols; forms and dose basis differIn the listed studies Table 1 specifies L-carnitine; some regimens included diet or physical activity. Salt mass and free carnitine content in the corresponding rows are not equated; do not automatically treat these regimens as identical.
Duration and population3–24 weeksAdults with different health status, including healthy participants and patients; 267 participants reported by the review for this outcome. The number of independent participants in the analysis is unconfirmed.

Comparison with control

Body fat percentage2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the overall estimate of body fat percentage due to study quality limitations and imprecision; the absence of a clear effect does not mean equivalence has been proven.

No clear effect was established.

Study findings. No clear effect was established.

Studied regimen1000–3000 mg/day in the listed protocols; forms and dose basis differIn the listed studies Table 1 specifies L-carnitine and glycine propionyl-L-carnitine [98]; some regimens included co-interventions. Salt mass and free carnitine content in the corresponding rows are not equated; do not automatically treat these regimens as identical.
Duration and population3–12 weeksAdults with different health status, including healthy participants and patients; 236 participants reported by the review for this outcome. The number of independent participants in the analysis is unconfirmed.

Comparison with control

Waist circumference1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowVery low confidence in the average waist circumference estimate because of quality limitations, substantial heterogeneity and an unstable range; statistical non-significance does not prove absence of an effect.

No clear effect was established.

Study findings. No clear effect was established.

Studied regimen250–2000 mg/day in the listed protocols; forms and dose basis differIn the studies listed for waist circumference Table 1 specifies L-carnitine; some trials included diet or physical activity. Salt mass and free carnitine content in the corresponding rows are not equated; do not automatically treat these regimens as identical.
Duration and population4–26 weeksAdults with different health status, including healthy participants and patients; 395 participants reported by the review for this outcome. The number of independent participants in the analysis is unconfirmed.

Comparison with control

Body mass index2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the pooled BMI result because of quality limitations and very high heterogeneity. The overall estimate does not establish an effect of a particular form or clinical significance.

In the pooled analysis BMI was slightly lower.

Study findings. In the pooled analysis BMI was slightly lower.

Studied regimen250–3000 mg/day in the listed protocols; forms and dose basis differThe set includes L-carnitine, acetyl-L-carnitine [82], L-carnitine L-tartrate [80,83], propionyl-L-carnitine [90] and glycine propionyl-L-carnitine [98], as well as co-interventions. Salt mass and free carnitine content in the corresponding rows are not equated; do not automatically treat these regimens as identical.
Duration and population3–48 weeksAdults with different health status, including healthy participants and patients; 2120 participants reported by the review for this outcome. The number of independent participants in the analysis is unconfirmed.

Comparison with control

Physical fatigue3/4 ModerateRead moreCollapse
Confidence
3/4 ModerateModerate confidence in the comparison of physical fatigue in this single trial: the range of possible magnitudes is insufficiently constrained. The result concerns centenarians, and the discrepancy in the name of the form between the primary abstract and the secondary report remains unresolved.

In this trial, the relevant fatigue rating decreased more with levocarnitine.

Study findings. In this trial, the relevant fatigue rating decreased more with levocarnitine.

Studied regimen2 g/dayOral levocarnitine
Duration and population24 weeks66 centenarians with fatigue on light exertion, 32/34

Comparison with placebo

Mental fatigue3/4 ModerateRead moreCollapse
Confidence
3/4 ModerateModerate confidence in the comparison of mental fatigue in this single trial: the range of possible magnitudes is insufficiently constrained. The result concerns centenarians, and the discrepancy in the name of the form between the primary abstract and the secondary report remains unresolved.

In this trial, the relevant fatigue rating decreased more with levocarnitine.

Study findings. In this trial, the relevant fatigue rating decreased more with levocarnitine.

Studied regimen2 g/dayOral levocarnitine
Duration and population24 weeks66 centenarians with fatigue on light exertion, 32/34

Comparison with placebo

Fatigue severity3/4 ModerateRead moreCollapse
Confidence
3/4 ModerateModerate confidence in the comparison of fatigue severity in this single trial: the range of possible magnitudes is insufficiently constrained. The result concerns centenarians, and the discrepancy in the name of the form between the primary abstract and the secondary report remains unresolved.

In this trial, the relevant fatigue rating decreased more with levocarnitine.

Study findings. In this trial, the relevant fatigue rating decreased more with levocarnitine.

Studied regimen2 g/dayOral levocarnitine
Duration and population24 weeks66 centenarians with fatigue on light exertion, 32/34

Comparison with placebo

Safety and limitations

In a six-month study of people with metabolic syndrome and existing carotid plaque, an exploratory analysis showed greater progression of arterial narrowing with L-carnitine. This result requires confirmation and does not prove an increase in heart attacks. In this six-month trial serious events were few; data are insufficient to assess rare or long-term harm. Increased TMAO is a biomarker, not proof of a causal increase in heart attacks or mortality; the ECoM RCT was not designed for rare events. Approximately 3 g carnitine daily may cause nausea, abdominal cramps, diarrhea and a fishy odor. Seizures have been reported with levocarnitine in people with and without previous seizures, as well as rash, hives and facial swelling. These reports do not establish the frequency of rare reactions; small trials do not establish long-term safety. If you experience seizures, discuss use with a doctor beforehand. Seek immediate medical help for seizures, facial swelling or other signs of a severe allergic reaction. ECoM 2 g/day for 6 months, 177 randomized: serious events and secondary vascular outcomes require study, but the sample and duration are insufficient to assess rare or long-term harm; this proves neither safety nor causality. NIH notes uncertainty about vascular risk. With severe kidney impairment, long-term high-dose oral levocarnitine may lead to accumulation of potentially toxic metabolites TMA and TMAO. This is a separate risk to discuss with the treating clinician. Adequate evidence of supplement safety during pregnancy and breastfeeding has not been established; medicinal use in children with deficiency does not prove supplement safety in healthy children. In a small study adding propionyl-L-carnitine to sildenafil, two people in the combination group reported mild abdominal pain; none stopped the study drugs. In the study described by LPI, women receiving taxanes for breast cancer who took acetyl-L-carnitine 3 g daily for 24 weeks had worse peripheral neuropathy and functional-status measures than with placebo. This risk concerns acetyl-L-carnitine in the specified combination and cannot be extrapolated to all carnitine forms. If you receive taxanes, discuss acetyl-L-carnitine with your oncologist before starting.

Progression of atherosclerosis with carnitine supplementation: a randomized controlled trial in the metabolic syndrome ↗ · Carnitine - Health Professional Fact Sheet ↗ · DailyMed: LEVOCARNITINE tablet ↗ · Preliminary observations on the use of propionyl-L-carnitine in combination with sildenafil in patients with erectile dysfunction and diabetes ↗ · L-Carnitine | Linus Pauling Institute | Oregon State University ↗

Interactions

WithEffectActionSource
WarfarinIncreased INR has been reported with levocarnitine.Discuss INR monitoring with a doctor after starting levocarnitine or changing its dose.DailyMed: LEVOCARNITINE tablet ↗
Pivalate-containing antibiotics, such as pivampicillinProlonged use may deplete carnitine stores.Discuss carnitine status with the treating clinician.Carnitine - Health Professional Fact Sheet ↗
Valproic acid, phenobarbital, phenytoin and carbamazepineThese antiseizure medicines may lower blood carnitine levels.Discuss the need for assessment with a doctor; do not change your treatment regimen on your own.Carnitine - Health Professional Fact Sheet ↗

Food sources

Dietary carnitine occurs in a range of animal and plant foods; its amount depends on the food.

Carnitine is found mainly in meat, with less in dairy products and poultry. Dietary amounts are not equivalent to doses studied in supplement research.

Carnitine - Health Professional Fact Sheet ↗

Poultry Chicken breast contains carnitine.

Carnitine - Health Professional Fact Sheet ↗

Fish Carnitine is found, for example, in cod.

Carnitine - Health Professional Fact Sheet ↗

Dairy products Whole milk, cheese and ice cream contain carnitine.

Carnitine - Health Professional Fact Sheet ↗

Plant foods Whole-grain bread and asparagus contain comparatively little carnitine; LPI also lists avocado.

Carnitine - Health Professional Fact Sheet ↗
L-Carnitine | Linus Pauling Institute | Oregon State University ↗

Fermented soy products L-carnitine was found in studied samples of miso and soy sauce; results apply to those particular samples.

Enantioselective Determination of Carnitine Enantiomers in Food and Supplement Samples by Chiral Liquid Chromatography-Tandem Mass Spectrometry ↗

Studies

PublicationWhat was studiedParticipantsForm and doseResult
Acute L-Carnitine Supplementation Does Not Improve CrossFit Performance: A Randomized, Double-Blind, Placebo-Controlled Crossover Study ↗randomized controlled trialCrossFit repetition count20 trained men, crossover RCToral L-carnitine L-tartrate; 3 g once; single dose; comparison: placebo; 7-day washout between periodsIn 20 trained men, a single 3 g dose of L-carnitine tartrate did not increase repetitions in a 20-minute task.
Acute and Chronic L-Carnitine Supplementation Enhances Endurance Performance Without Consistent Effects on Substrate Oxidation in Active Individuals: A Systematic Review ↗systematic reviewIndividual endurance testsActive people; 18 studies refer to the whole review, and numbers of participants and studies for individual tests are not specified in the abstract.Oral L-carnitine, protocols varied; 2–15 g once or 2–3 g/day in the review; Acute protocols and 2–24-week courses; comparison: placeboPositive results were observed in individual tests; the magnitude of the overall effect was not established.

Sources

Sources
  1. Acute L-Carnitine Supplementation Does Not Improve CrossFit Performance: A Randomized, Double-Blind, Placebo-Controlled Crossover Study ↗
  2. Acute and Chronic L-Carnitine Supplementation Enhances Endurance Performance Without Consistent Effects on Substrate Oxidation in Active Individuals: A Systematic Review ↗
  3. Effects of nine weeks L-Carnitine supplementation on exercise performance, anaerobic power, and exercise-induced oxidative stress in resistance-trained males ↗
  4. Responses of criterion variables to different supplemental doses of L-carnitine L-tartrate ↗
  5. Effects of L-carnitine supplementation on markers of exercise-induced muscle damage in healthy adults: A systematic review and meta-analysis of randomized controlled trials ↗
  6. L-Carnitine Tartrate Supplementation for 5 Weeks Improves Exercise Recovery in Men and Women: A Randomized, Double-Blind, Placebo-Controlled Trial ↗
  7. Effects of Citric Acid and l-Carnitine on Physical Fatigue ↗
  8. Progression of atherosclerosis with carnitine supplementation: a randomized controlled trial in the metabolic syndrome ↗
  9. Carnitine - Health Professional Fact Sheet ↗
  10. L-carnitine for cognitive enhancement in people without cognitive impairment ↗
  11. DailyMed: LEVOCARNITINE tablet ↗
  12. Preliminary observations on the use of propionyl-L-carnitine in combination with sildenafil in patients with erectile dysfunction and diabetes ↗
  13. L-Carnitine | Linus Pauling Institute | Oregon State University ↗
  14. Enantioselective Determination of Carnitine Enantiomers in Food and Supplement Samples by Chiral Liquid Chromatography-Tandem Mass Spectrometry ↗
  15. Effects of l-carnitine supplementation on weight loss and body composition: A systematic review and meta-analysis of 37 randomized controlled clinical trials with dose-response analysis ↗
  16. L-carnitine treatment reduces severity of physical and mental fatigue and increases cognitive functions in centenarians: a randomized and controlled clinical trial ↗